Zyrovazet 10/40 Mg 30 Tablets

Zyrovazet 10/40 Mg 30 Tablets

Description:

Zyrovazet 10/40 mg 30 tablets is a prescription oral lipid-lowering medicine that combines ezetimibe and rosuvastatin in a single film-coated tablet. It is used to reduce high cholesterol and triglyceride levels and to help prevent cardiovascular events in patients at risk. Zyrovazet works by both inhibiting the absorption of cholesterol from the intestine (via ezetimibe) and decreasing cholesterol synthesis in the liver (via rosuvastatin), providing dual and complementary control of dyslipidemia when diet and lifestyle measures alone are not sufficient.

Indications:

• Primary hypercholesterolemia (including heterozygous familial and non-familial) as an adjunct to diet when combination therapy with ezetimibe and rosuvastatin is appropriate.
• Mixed dyslipidemia (elevated total cholesterol, ldl-cholesterol, triglycerides, and/or low hdl-cholesterol) in adults when a fixed-dose combination is clinically indicated.
• Homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., apheresis) or when such treatments are not available or not tolerated.
• Reduction of elevated ldl-cholesterol in patients not adequately controlled on statin monotherapy or ezetimibe alone.
• Cardiovascular risk reduction (e.g., reduction of risk of myocardial infarction, stroke, or need for revascularization) in high-risk patients with dyslipidemia, as part of comprehensive risk factor management according to physician guidance.

Active Ingredients / Key Components:

• Ezetimibe – 10 mg per film-coated tablet (cholesterol absorption inhibitor).
• Rosuvastatin – 40 mg per film-coated tablet (hmg-coa reductase inhibitor, statin).
• Other excipients: film-coating and tablet core excipients (specific inactive ingredients and their concentrations , please check the product leaflet or the manufacturer’s official website).

Dosage & Administration / How to Use:

• Zyrovazet 10/40 mg is for oral use only and should be swallowed whole with a glass of water. Do not crush, chew, or split the tablets.
• It can be taken with or without food, preferably at the same time each day to help adherence.
• The usual dose is one tablet of Zyrovazet 10/40 mg once daily, or as directed by your physician based on your lipid profile, cardiovascular risk, and response to therapy.
• Patients already stabilized on separate ezetimibe 10 mg and rosuvastatin 40 mg may be switched to the corresponding Zyrovazet 10/40 mg fixed-dose combination as decided by the treating physician.
• If you are taking a bile acid sequestrant (e.g., cholestyramine), take Zyrovazet at least 2 hours before or 4 hours after the bile acid sequestrant to avoid reduced absorption of ezetimibe.
• Do not exceed the prescribed dose. Do not stop taking the medicine without consulting your doctor, even if you feel well, as cholesterol reduction is a long-term therapy.
• If you miss a dose, take it as soon as you remember on the same day. If it is almost time for the next dose, skip the missed dose and resume your regular schedule. Do not double the dose to make up for a missed tablet.
• Dosage adjustments or special monitoring may be required in patients with renal impairment, hepatic impairment, elderly patients, or those taking interacting medicines. Follow your doctor’s instructions carefully.

Clinical Benefits:

• Provides dual lipid-lowering action by reducing intestinal cholesterol absorption (ezetimibe) and hepatic cholesterol synthesis (rosuvastatin), leading to more potent ldl-cholesterol reduction than either agent alone.
• Helps significantly lower total cholesterol, ldl-cholesterol, non-hdl cholesterol, and triglycerides, while modestly increasing hdl-cholesterol, supporting overall lipid profile improvement.
• Assists in reducing the risk of atherosclerotic cardiovascular disease events (such as heart attack and stroke) when used as part of a comprehensive risk management plan including diet, exercise, and control of other risk factors.
• Convenient fixed-dose combination in a single daily tablet improves treatment adherence compared to taking separate ezetimibe and statin tablets.

Warnings & Contraindications:

• Contraindicated in patients with known hypersensitivity to ezetimibe, rosuvastatin, or any excipient in the formulation.
• Contraindicated in active liver disease or unexplained persistent elevations of serum transaminases.
• Contraindicated during pregnancy and breastfeeding, as statins may harm the fetus or nursing infant. Women of childbearing potential should use effective contraception during treatment.
• Use with caution in patients with a history of liver disease, heavy alcohol use, renal impairment, hypothyroidism, or a personal or family history of hereditary muscle disorders.
• Risk of myopathy and rhabdomyolysis is increased with high-dose statin therapy (including rosuvastatin 40 mg), especially when combined with certain medicines (e.g., cyclosporine, some antivirals, fibrates, niacin, or other lipid-lowering drugs). Inform your doctor about all medications and supplements you are taking.
• Periodic monitoring of liver function tests and creatine kinase (ck) may be recommended, especially at treatment initiation or dose escalation, or if symptoms suggestive of liver or muscle injury occur.
• Stop the medicine and seek medical advice immediately if you develop unexplained muscle pain, tenderness, weakness, dark-colored urine, severe fatigue, or jaundice.
• Consult your doctor before use if pregnant, nursing, planning pregnancy, taking other lipid-lowering medications, anticoagulants, immunosuppressants, antivirals, or if you have medical conditions such as liver disease, kidney disease, thyroid disorders, or uncontrolled diabetes.
• Not intended to diagnose, treat, cure, or prevent any disease without proper medical supervision. This is a prescription medicine and must be used only under the guidance of a qualified healthcare professional.
• Keep out of reach of children. Accidental ingestion by children may be harmful and requires immediate medical attention.

Side Effects:

• Common side effects may include headache, dizziness, abdominal pain, constipation, nausea, diarrhea, flatulence, muscle pain (myalgia), joint pain, and fatigue.
• Less common side effects can include elevation of liver enzymes, increased creatine kinase, rash, itching, or hypersensitivity reactions.
• Serious but rare side effects include myopathy, rhabdomyolysis (severe muscle breakdown), severe liver injury, pancreatitis, and severe allergic reactions (e.g., angioedema). Seek immediate medical attention if you experience severe muscle pain or weakness, dark urine, yellowing of the skin or eyes, severe abdominal pain, difficulty breathing, or facial/lip swelling.
• This is not a complete list of side effects. Always read the patient information leaflet inside the pack and consult your doctor or pharmacist if you notice any unusual symptoms.

Storage Instructions:

Store in a cool, dry place away from direct sunlight and moisture. Keep the tablets in their original blister pack and outer carton to protect from light. Do not store above the temperature specified on the package (exact temperature range is not available in the provided information; follow pack instructions). Keep container tightly closed and keep out of reach of children.

Specifications:

• Serving size: 1 tablet.
• Count: 30 film-coated tablets per pack.
• Form: Oral tablet (film-coated).
• Strength per tablet: ezetimibe 10 mg + rosuvastatin 40 mg.
• Intended use: prescription lipid-lowering medicine for adults, as directed by a healthcare professional.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.